Stefan S. De Buck - Concepedia

Concepedia

Author

Stefan S. De Buck

Novartis (Switzerland)

Also Known As

S. S. De Buck, Stefan S De Buck, Stefan S. De Buck

13

Publications

1.3K

Citations

11

H-Index

30

Concepts

All Affiliations

Novartis (Switzerland)Laboratoire National de Santé Janssen (Belgium)

SS

About

Stefan S. De Buck is an author at Novartis (Switzerland) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	107
2	Allergy	1	1	10
3	Cell Biology	1	1	10
4	Cellular Physiology	1	1	10
5	Immunology	1	1	10

Stefan S. De Buck

×

11

Publications

1.3K

Citations

10

H-Index

	Year	Citations
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors Johanna C. Bendell, Jordi Rodón, Howard A. Burris, Journal of Clinical Oncology	2011	679
Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs Stefan S. De Buck, Vikash K. Sinha, Luca A. Fenu, Drug Metabolism and Disposition	2007	251
The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools Stefan S. De Buck, Vikash K. Sinha, Luca A. Fenu, Drug Metabolism and Disposition	2007	92
A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. José Baselga, Maja J. De Jonge, Jordi Rodón, Journal of Clinical Oncology PathologyPi3k InhibitorPharmacotherapyAdvanced Solid TumorsTumor Biology	2010	53
Predicting Oral Clearance in Humans Vikash K. Sinha, Stefan S. De Buck, Luca A. Fenu, Clinical Pharmacokinetics Oral CavityOral HygieneOral ClearanceOral BiologySpeech Perception	2008	49
Population pharmacokinetics and pharmacodynamics of<scp>BYL</scp>719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies Stefan S. De Buck, Annamária Jakab, Markus Boehm, British Journal of Clinical Pharmacology	2014	35
Specific Antibody Modulates Absorptive Transport and Metabolic Activation of Benzo[a]pyrene across Caco-2 Monolayers Stefan S. De Buck, Patrick Augustijns, Claude P. Muller Journal of Pharmacology and Experimental Therapeutics	2005	24
A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. Philippe L. Bédard, Josep Tabernero, Razelle Kurzrock, Journal of Clinical Oncology PathologyPharmacotherapyMaximum Tolerated DoseAdvanced Solid TumorsTumor Biology	2012	23
Towards a Better Prediction of Peak Concentration, Volume of Distribution and Half-Life after Oral Drug Administration in Man, Using Allometry Vikash K. Sinha, Karin Vaarties, Stefan S. De Buck, Clinical Pharmacokinetics Using AllometrySubstance AbusePharmacokinetic ModelingPharmacological StudyAddiction	2011	21
Modulation of the metabolism and adverse effects of benzo[a]pyrene by a specific antibody: a novel host factor in environmental carcinogenesis? Stefan S. De Buck Carcinogenesis	2005	18

Page 1